胚胎植入前非整倍体遗传学检测的认知、动机与决策后悔
该单中心匿名在线调查纳入115名接受IVF的患者,比较完成与未完成PGT-A者的决策后悔程度。约三分之一参与者表达中重度后悔,未完成PGT-A者后悔评分更高,主要由未检测后发生流产者驱动。
要点
- 未完成PGT-A者决策后悔评分中位数显著高于完成者(15 vs 0,P=0.013)。
- 未完成PGT-A者轻度后悔(36% vs 16%)和中重度后悔(32% vs 24%)比例均更高(P=0.011)。
- 未完成PGT-A且有流产史者后悔评分中位数显著更高(45 vs 0,P=0.018)。
核心结论
- 约三分之一参与者对完成或未完成PGT-A的决策表达中重度后悔,未完成PGT-A者后悔更高,主要由未检测后流产者驱动。
研究设计与样本
- 单中心匿名在线调查,2016年1月至2017年12月向1583名接受IVF(伴或不伴PGT-A)的患者发放问卷,最终纳入115名分析(完成PGT-A 55名,未完成60名)。
主要发现
- 完成PGT-A组平均年龄略高于未完成组(37±3.7岁 vs 36±3.4岁,P=0.048),流产率更低(5% vs 22%,P=0.012)。
- 两组均强烈相信PGT-A的益处,完成组对降低出生缺陷风险(中位数82 vs 77,P=0.046)、提高健康婴儿机会(89 vs 74,P=0.002)和选择最佳胚胎(85 vs 80,P=0.049)的相信程度更高。
- 完成组更受不移植异常胚胎的愿望驱动(中位数84 vs 53,P=0.0001),医生咨询在两组均重要(70 vs 71,P=0.671)。
- 未完成PGT-A组决策后悔评分中位数更高(15 vs 0,P=0.013),轻度后悔(36% vs 16%)和中重度后悔(32% vs 24%)比例更高(χ2=9.03,df=2,P=0.011)。
- 未完成PGT-A且有流产史者后悔评分中位数更高(45 vs 0,P=0.018);多因素logistic回归未发现任何人口学因素、临床结局或认知/动机独立预测中重度后悔风险。
临床怎么用
- 作者建议医生更仔细考虑个体患者对冒险或规避风险行为的价值观,以及自身对PGT-A的立场。
- 在PGT-A使用有明确推荐前,作者推荐医生与遗传咨询师密切合作,以平衡和个体化方式教育患者PGT-A的风险与潜在益处。
局限性
- 回顾性数据收集可能带来抽样和回忆偏倚。
- 仅59%符合条件的应答者完成完整调查,可能主要是那些治疗后情绪非常正面或负面者才填写。
- 该偏倚适用于整个群体,而非仅完成或未完成PGT-A者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is there a difference in level of decision regret following IVF treatment between those who choose to complete or not complete preimplantation genetic testing for aneuploidy [PGT-A]? SUMMARY ANSWER: Approximately one-third of the participants expressed moderate to severe regret (MSR) following their decision to either complete or not complete PGT-A; notably, decision regret was higher in those who chose not to complete PGT-A, primarily driven by significantly higher regret scores in those that experienced a miscarriage after not testing. WHAT IS KNOWN ALREADY: Previous research has found that 39% of participants who completed PGT-A expressed some degree of decision regret and that negative clinical outcomes, such as lack of euploid embryos, negative pregnancy test or miscarriage, were associated with a higher level of decision regret. To date, there are no published studies assessing the possible disparity in decision regret surrounding PGT-A in a population of IVF patients that either chose to pursue PGT-A or not. STUDY DESIGN, SIZE, DURATION: An anonymous online survey was distributed to 1583 patients who underwent IVF with or without PGT-A at a single university institution between January 2016 and December 2017. In total, 335 women accessed the survey, 220 met eligibility criteria and 130 completed the full study survey. Six participants were excluded due to refusal of medical record review, and nine participants were excluded after record review due to not meeting eligibility based on cycle start date or completing only embryo banking without attempting transfer. One hundred and fifteen participants were included in the final analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: Of the 115 participants included, 55 (48%) completed PGT-A and 60 (52%) did not complete PGT-A. The online survey included four sections: Demographics; Perceptions about PGT-A risks and benefits [scale from 0 (absolutely not true) to 100 (absolutely true)]; Decision-making factors [scale from 0 (not important) to 100 (very important)]; and Brehaut Decision Regret Scale [DRS] [range 0-100, with >25 indicating MSR]. A retrospective chart review was conducted to confirm study eligibility and collect cumulative clinical outcomes of consenting participants who completed the survey. MAIN RESULTS AND THE ROLE OF CHANCE: Demographics of the PGT-A and no PGT-A cohorts were similar, with the majority of respondents being Caucasian or Asian, unaffiliated with any religion and with a graduate or professional degree. The two groups differed significantly in mean age, with the PGT-A group being slightly older (mean ± SD: 37 ± 3.7 versus 36 ± 3.4; P = 0.048), and in rate of miscarriages, with fewer participants in the PGT-A cohort experiencing a miscarriage (5% versus 22%; P = 0.012). The majority of participants in both PGT-A and no PGT-A cohorts strongly believed in the purported benefits of PGT-A, including that it decreases the risk of birth defects (median 82 versus 77; P = 0.046), improves the chances of having a healthy baby (median 89 versus 74; P = 0.002) and selects the best embryo for transfer (median 85 versus 80; P = 0.049). When asked to report their motivating factors for decision-making, both groups cited physician counseling as important (median 70 versus 71; P = 0.671); however, the PGT-A cohort was more strongly motivated by a desire to not transfer abnormal embryos (median 84 versus 53; P = 0.0001). Comparison of DRS score between those who did or did not undergo PGT-A showed significantly higher median DRS score after not completing PGT-A (median 15 versus 0; P = 0.013). There was a significantly higher proportion of participants who did not complete PGT-A that expressed mild (36% versus 16%) and MSR (32% versus 24%) compared to those who completed PGT-A (χ2 = 9.03, df = 2; P = 0.011). Sub-group analyses of DRS scores by outcomes of clinical pregnancy, miscarriage and live birth revealed that the higher DRS score in those not completing PGT-A was driven by a large increase in regret noted by those with history of a miscarriage (median 45 versus 0; P = 0.018). Multivariate logistic regression modeling found no evidence that any specific demographic factor, clinical outcome or perception/motivation surrounding PGT-A was independently predictive of increased risk for MSR. LIMITATIONS, REASONS FOR CAUTION: The retrospective nature of data collection incurs the possibility of sampling and recall bias. As only 59% of eligible respondents completed the full survey, it is possible that mainly those with very positive or negative sentiments following treatment felt compelled to complete their response. This bias, however, would apply to the whole of the population, and not simply to those who did or did not complete PGT-A. WIDER IMPLICATIONS OF THE FINDINGS: The proportion of participants expressing any degree of decision regret in this PGT-A cohort was 40%, which is comparable to that shown in prior research. This study adds to prior data by also assessing decision regret experienced by those who went through IVF without PGT-A, and showed that 68% expressed some level of regret with their decision-making. These results should not be interpreted to mean that all patients should opt for PGT-A to pre-emptively mitigate their risk of regret. Instead, it suggests that drivers of decision regret are likely multifactorial and unique to the experience of one's personal expectations regarding PGT-A, motivations for pursuing or not pursuing it and resultant clinical outcome. Highlighting the complex nature of regret, these data should encourage physicians to more carefully consider individual patient values toward risk-taking or risk-averse behavior, as well as their own positions regarding PGT-A. Until there are clear recommendations regarding utilization of PGT-A, a strong collaboration between physicians and genetic counselors is recommended to educate patients on the risks and potential benefits of PGT-A in a balanced and individualized manner. STUDY FUNDING/COMPETING INTEREST(S): No funding was utilized for study completion and the authors have no competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- Kaing A, Rosen MP, Quinn MM, et al. Perceptions, motivations and decision regret surrounding preimplantation genetic testing for aneuploidy. Hum Reprod. 2020. PMID: 32756971. doi:10.1093/humrep/deaa154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。